Division of Nephrology, Asia University Hospital, Taichung, Taiwan.
Department of Post-baccalaureate Veterinary Medicine, Asia University, Taichung, Taiwan.
Rapid Commun Mass Spectrom. 2020 Apr;34 Suppl 1:e8580. doi: 10.1002/rcm.8580. Epub 2020 Feb 5.
Chronic pancreatitis (CP) is a pancreatic disease with poor prognosis and pancreatic cancer (PC) is one of the most lethal types of cancer that is symptomless in the early stage. Because the clinical and image findings of CP can overlap that of pancreatic cancer (PC) which leads to confusion in the diagnosis and treatment of PC, discovery/verification/validation of more accurate protein biomarkers to diagnose CP and PC is in urgent need.
The PubMed, Web of Science, and Google Scholar were searched using the keywords: 'biomarker', 'marker', 'chronic pancreatitis', "pancreatic cancer" or "proteomics" for highly related researches. We focused on the articles published after the year 2005 in this review.
We introduce the background to CP and PC and summarize the diagnosis of CP and PC, analytically validated protein biomarkers, and proteomic approaches for discovery/verification/validation. The potential use of mass spectrometry (MS) in clinical diagnosis is also discussed.
Continuously improving sensitivity of MS can provide deeper proteome for new marker discovery and high reliability for protein marker verification, validation, and clinical diagnosis. The analytically validated protein markers could be considered as targeted protein biomarkers for developing a MS platform in the clinical validation process or clinical diagnosis of CP and PC.
慢性胰腺炎(CP)是一种预后不良的胰腺疾病,胰腺癌(PC)是最致命的癌症类型之一,早期无症状。由于 CP 的临床和影像学表现可能与胰腺癌(PC)重叠,导致 PC 的诊断和治疗混淆,因此迫切需要发现/验证/确证更准确的蛋白生物标志物来诊断 CP 和 PC。
使用“biomarker”、“marker”、“chronic pancreatitis”、“pancreatic cancer”或“proteomics”等关键词在 PubMed、Web of Science 和 Google Scholar 上搜索高度相关的研究。我们重点关注了本综述中发表于 2005 年以后的文章。
我们介绍了 CP 和 PC 的背景,并总结了 CP 和 PC 的诊断、分析验证的蛋白生物标志物以及发现/验证/确证的蛋白质组学方法。还讨论了质谱(MS)在临床诊断中的潜在用途。
不断提高 MS 的灵敏度可以为新标志物的发现提供更深层次的蛋白质组学信息,为蛋白标志物的验证、确证和临床诊断提供更高的可靠性。分析验证的蛋白标志物可以被认为是开发 MS 平台的靶向蛋白生物标志物,用于 CP 和 PC 的临床验证过程或临床诊断。